OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
📊 Key Statistics
Market Cap—
P/E Ratio—
EPS (TTM)—
EPS YoY—
Revenue YoY—
Float—
Short Float %—
Inst. Ownership—
Sector RS—
📈 Fundamentals
ROE—
ROIC—
ROA—
Current Ratio—
Debt/Equity—
Gross Margin—
Net Margin—
Dividend Yield—
Next Earnings—
⚡ Options Summary
Call OI—
Put OI—
P/C Ratio (OI)—
Gamma Environment—
Max Pain—
Call Wall—
Put Wall—
🎯 Analyst Estimates
Consensus Target—
High Target—
Low Target—
Analysts—
Upside/Downside—
📋 Quarterly Financials
| Period |
Revenue |
Rev YoY |
EPS |
EPS YoY |
Gross Margin |
🔥 Recent Options Flow
| Type | Strike | Exp | Size | Premium | Time |
🏛️ Institutional Trades
| Type | Price | Size | Value | Venue | Time |
🏦 Top Institutional Holders
| Institution | Shares | Value | % of Class |